Mike Powell on cfDNA Biomarker Algorithm that Predicts Treatment Response in Lung Cancer

DiaCarta Inc., a precision molecular diagnostics company with proprietary technologies for the development of novel liquid biopsy oncology tests, recently published a study in Nature Scientific Reports that demonstrates that DiaCarta’s cfDNA biomarker algorithm could function as a prognostic biomarker and efficacy predictor for non-small cell lung cancer (NSCLC) patients. DocWire News spoke with Mike Powell, … Continue reading Mike Powell on cfDNA Biomarker Algorithm that Predicts Treatment Response in Lung Cancer